课题基金 / 基金详情

Understanding the treatment benefits of chimeric antigen receptor T-cells for lymphoma: quality of life, health utility, cost, and return to work

Understanding the treatment benefits of chimeric antigen receptor T-cells for lymphoma: quality of life, health utility, cost, and return to work
了解嵌合抗原受体 T 细胞治疗淋巴瘤的益处：生活质量、健康效用、成本和重返工作岗位
批准号：
438086
负责人：
Wong William Wai Lun
金额：
$7.29万
依托单位：
University of Waterloo (Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2020
资助国家：
加拿大
项目状态：
已结题
起止时间：
2020-10-01 至 2021-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=438086&lang=en
关键词：
Chimeric Antigen Receptor T-Cells Cost-Effectiveness Analysis Health Utility Out-Of-Pocket Costs Quality Of Life Time Costs

项目摘要

项目成果

Wong William Wai Lun的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The development of chimeric antigen receptor T-cells, or CAR T-cells has transformed oncology treatment, offering the potential to cure certain end-stage cancers including lymphoma. Because of the expense of these CAR T-cell therapies, and the large numb
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Towards establishing accurate estimates of national chronic hepatitis B prevalence and undiagnosed proportion in Canada
  • 批准号：
    488763
  • 项目类别：
    Operating Grants
  • 资助金额：
    $7.29万
  • 财政年份：
    2023
  • 负责人：
    Wong William Wai Lun
  • 依托单位：
    University of Waterloo (Ontario)
Developing policy models for sexually transmitted and blood-borne infection: integrating best evidence of effectiveness, safety, cost, and patient preferences
  • 批准号：
    499040
  • 项目类别：
    Salary Programs
  • 资助金额：
    $83.78万
  • 财政年份：
    2023
  • 负责人：
    Wong William Wai Lun
  • 依托单位：
    University of Waterloo (Ontario)
Evaluating the impact of direct-acting antiviral treatment access policy on chronic hepatitis C prevalence and the undiagnosed proportion
  • 批准号：
    475136
  • 项目类别：
    Operating Grants
  • 资助金额：
    $10.93万
  • 财政年份：
    2022
  • 负责人：
    Wong William Wai Lun
  • 依托单位：
    University of Waterloo (Ontario)
Improvements in quality of life, health utility, cost, and return to work for lymphoma patients after chimeric antigen receptor T- cells therapy in a real-world setting
  • 批准号：
    456739
  • 项目类别：
    Operating Grants
  • 资助金额：
    $7.29万
  • 财政年份：
    2021
  • 负责人：
    Wong William Wai Lun
  • 依托单位：
    University of Waterloo (Ontario)
海外基金